Horizontal Alveolar Ridge DeficiencyNCT04814160
Autobone and Bioactive Glass With Ridge Splitting
A study testing mixture of bioactive glass and autogenous bone graft and autogenous bone graft in people with Horizontal Alveolar Ridge Deficiency, run by Kafrelsheikh University at 1 site in Egypt.
Trial summary
Objective: To compare the use of autogenous bone graft versus autogenous bone graft mixed with bioactive glass bone graft in the treatment of maxillary anterior horizontal bone defects by ridge splitting technique combined with simultaneous implant placement. Read more about this study
- Who is it for?
- Ages 21 to 50 yearsHealthy volunteers can take part
- Conditions the study is for
- Horizontal Alveolar Ridge Deficiency
- What is being tested?
- mixture of bioactive glass and autogenous bone graft and autogenous bone graft
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 22 participants
- Where
- 1 siteEgypt
- Study dates
- 17 Apr 2020to 15 Apr 2021
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 to 50 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- good general health at the time of surgery
- at least 3months postextraction healing period
- horizontally compromised maxillary anterior alveolar ridges (at least 3mm bone width and 13mm bone vertical height).
Who cannot join
- vertical bone defect
- thick labial cortex with less cancellous bone inside
- obvious undercut on the labial/buccal side
- uncontrolled periodontal conditions
- history of radiotherapy in the head and neck region
- uncontrolled diabetes mellitus or other systematic disorders
Show all 10Show fewer
- smokers
- pregnancy
- non-compliant patients
- allergic reaction to the used medications.
Trial locations and contacts
1 site in 1 country.
Egypt1 site
faculty of dentistry, kafrelsheikh University
Kafr ash Shaykh, 214312
About this study
Official title: Ridge Splitting and Simultaneous Implant Placement With Autogenous Bone and Bioactive Glass for the Treatment of Maxillary Horizontal Bone Defects: A Randomised Clinical Trial
Objective: To compare the use of autogenous bone graft versus autogenous bone graft mixed with bioactive glass bone graft in the treatment of maxillary anterior horizontal bone defects by ridge splitting technique combined with simultaneous implant placement.
Materials and methods: Twenty-two patients were divided randomly into two groups; control group and study group. In control group, bone expansion was performed and autogenous bone was used to augment the intercortical bone defect. In study group, bone expansion was performed and autogenous bone mixed with bioactive glass was used to augment the intercortical bone defect. In both groups, the implants were inserted simultaneously with ridge splitting. 6 months after implant placement, the mean bone width and alveolar bone loss values were evaluated. Statistical analysis using paired Student's t- test to compare results within the same group of patients, whereas, independent samples t-test was used to compare variables between the two groups
Read the detailed description
Participants' selection:
22 patients, aged from 18 to 50 years, were selected in this prospective, randomized and blinded clinical trial from the Outpatient Clinic of the Department of Oral Medicine and Periodontology, Faculty of Dentistry, Kafrelsheikh University. Those subjects had inadequate bone volume for implant placement due to width insufficiency of maxillary anterior alveolar ridges. The research ethical committee of Faculty of Dentistry, Kafrelsheikh University approved the study (KD/06/21). Research procedures were explained to all patients, and they agreed to participate in the study and signed the appropriate informed consent form. The inclusion criteria implemented for patient selection were good general health at the time of surgery; at least 3months postextraction healing period; and horizontally compromised maxillary anterior alveolar ridges (at least 3mm bone width and 13mm bone height). The criteria of patients exclusion were vertical bone defect; thick labial cortex with less cancellous bone inside; obvious undercut on the labial/buccal side; uncontrolled periodontal conditions; history of radiotherapy in the head and neck region; uncontrolled diabetes mellitus or other systematic disorders; smokers; pregnancy; non-compliant patients; and allergic reaction to the used medications.
Pre-surgical therapy and grouping Pre-surgical therapy consisted of a thorough full-mouth scaling and root planning. Patients were randomly assigned immediately before surgery into two groups (11 patients each) by computer-assessed randomization software (Random Allocation Software, Version 1.0). Control group received ridge splitting with simultaneous implant placement in combination with autogenous bone graft alone, while study group used (1:1) mixture of autogenous and bioactive glass bone grafts. Bone volume was assessed two weeks before operation using CBCT (Scanora 3D, Soredex Oy, Tuusula, Finland).
Surgical procedure:
Operations were performed under local anesthesia. Mid-crestal incision followed by full thickness flap reflection to expose surgical site. Mid crestal cut using piezo-surgery unit (Piezotome® Cube, ACTEON®, Acteon Group Ltd, Norwich, England). Then, the cut was extended deep to the length of implant. Then, ridge was expanded progressively using bone wedges (Microdent Implant System, Spain). Implant location was marked, with a buccal bony wall as uniformly thick (>1 mm) as possible to avoid bone fracture. The implant site was prepared and 3.75*13 mm dental implant fixture (Humana Dental Implants \& Accessories GmbH, Germany) was placed stably in between the two bony plates.
Autogenous bone harvesting:
Incision was made at mucogingival junction in the symphysis area followed by full thickness flap reflection, and then corticocancellous bone was harvested using a trephine drill. Finally the flap was sutured by interrupted and horizontal mattress suture by 3-0 black silk.
In control group, harvested autogenous bone graft was used for augmentation of the gap between buccal and lingual plates. Study group received the same way of treatment except using (1:1) mixture of the harvested autogenous bone with bioactive glass bone graft (BonyGlass, Pharma-Excellence, Egypt). The wound was completely closed in a tension-free way. All surgeries were performed by the same operator.
Postoperative care:
Patients were prescribed amoxicillin-clavulanic acid 1g. every 12hours antibiotic (Augmentin 1g, SmithKline Beecham Pharmaceuticals), and 0.12% chlorhexidine hydrochloride mouth wash twice daily (Hexitol, ADCO, Cairo, A.R.E). The sutures were removed 14days postoperatively. No removable denture was allowed to wear for 2weeks.
6months postoperatively, clinical evaluation was recorded including implant survival, presence of infection, pain, tenderness or wound dehiscence. CBCT was taken at 6months postoperatively to evaluate ridge width and bone level. All clinical and radiographic measurements were recorded by one calibrated masked examiner.
Study variables The primary outcome variable was linear changes in the marginal bone surrounding the implants and alveolar ridge width, taken from cross-sectional and longitudinal CBCT images. Bone heights and width were assessed preoperatively and after 6months postoperatively using the CBCT images.
Statistical analysis:
Sample size calculation was undertaken via G power version 3.1 statistical software based on the following pre-established parameters: an alpha-type error of 0.05, a power test of 0.80, a total sample of 22 subjects (11 subjects for each group) appeared to be sufficient.
The statistical analysis was performed using IBM SPSS version 20 software (IBM Corp., Armonk, NY, USA). Data were presented as the mean+stanstandard deviation. The paired Student's t- test was used to compare the obtained results within the same group of patients at 2 different intervals. The independent samples t-test was used to compare variables between the two groups. In all tests, the result was considered statistically significant if the P-value was <0.05.
- Conditions
- Horizontal Alveolar Ridge Deficiency
- Being tested
- mixture of bioactive glass and autogenous bone graft, autogenous bone graft
- Keywords
- Ridge split, dental implant, piezosurgery, bioactive glass, autogenous bone
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
mixture of bioactive glass and autogenous bone graftProcedure or surgery
bone expansion was performed and autogenous bone mixed with bioactive glass was used to augment the intercortical bone defect after ridge splitting and simultaneous dental implants
autogenous bone graftProcedure or surgery
bone expansion was performed and autogenous bone alone was used to augment the intercortical bone defect after ridge splitting and simultaneous dental implants
| Study group | Role | What they receive |
|---|---|---|
| autogenous bone graft | Active comparator | autogenous bone graft for augmenting bone defects around dental implants placed simultaneously with ridge splitting Receives: Procedure: autogenous bone graft |
| mix of bioactive glass and autogenous bone graft | Experimental | 1:1 mix of bioactive glass and autogenous bone graft for augmenting bone defects around dental implants placed simultaneously with ridge splitting Receives: Procedure: mixture of bioactive glass and autogenous bone graft |
What is being measured
The primary outcome is the main question the study is designed to answer.
Clinical measurements of pain intensity
pain intensity verbal rating scale either mild, moderate or sever
Measured: 6 months
Clinical incidence of implants mobility
Implants mobility
Measured: 6 months
measuring the survival rates
survival rates of implants
Measured: 6 months
Secondary outcomes (1)
radiographic results of bone width and height
evaluation of bone width and height using CBCT
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Mar 2021
- Study start17 Apr 2020
- Primary completion10 Apr 2021
- Study completion15 Apr 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Horizontal Alveolar Ridge DeficiencyStudies of the same condition, open and under way.
- More trials run by Kafrelsheikh UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Factorial
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 22 participants (actual)
Sponsor and investigators
- Lead sponsor
- Kafrelsheikh University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Walid Elamrousy, Kafrelsheikh University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04814160
- Sponsor's protocol ID
- RSBG2021
- Status last verified
- May 2021
- First submitted
- 16 Mar 2021
- Last updated
- 4 May 2021
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Elamrousy W, Osama M, Issa DR. Autogenous Bone and Bioactive Glass around Implants Placed Simultaneously with Ridge Splitting for the Treatment of Horizontal Bony Defects: A Randomised Clinical Trial. Int J Dent. 2021 Jul 28;2021:2457328. doi: 10.1155/2021/2457328. eCollection 2021.
PubMed 34367287
Study at a glance
From the registry record, last updated by the sponsor on 4 May 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Ridge Splitting and Simultaneous Implant Placement With Autogenous Bone and Bioactive Glass for the Treatment of Maxillary Horizontal Bone Defects: A Randomised Clinical Trial
- ClinicalTrials.gov ID
- NCT04814160
- Acronym / sponsor ID
- RSBG2021
- Conditions
- Horizontal Alveolar Ridge Deficiency
- Keywords
- Ridge split, dental implant, piezosurgery, bioactive glass, autogenous bone
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 22 participants (actual)
- Lead sponsor
- Kafrelsheikh UniversityUniversity, hospital or other
- Study start
- 17 Apr 2020 (actual)
- Primary completion
- 10 Apr 2021 (actual)
- Study completion
- 15 Apr 2021 (actual)
- First posted
- 24 Mar 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Objective: To compare the use of autogenous bone graft versus autogenous bone graft mixed with bioactive glass bone graft in the treatment of maxillary anterior horizontal bone defects by ridge splitting technique combined with simultaneous implant placement.
Materials and methods: Twenty-two patients were divided randomly into two groups; control group and study group. In control group, bone expansion was performed and autogenous bone was used to augment the intercortical bone defect. In study group, bone expansion was performed and autogenous bone mixed with bioactive glass was used to augment the intercortical bone defect. In both groups, the implants were inserted simultaneously with ridge splitting. 6 months after implant placement, the mean bone width and alveolar bone loss values were evaluated. Statistical analysis using paired Student's t- test to compare results within the same group of patients, whereas, independent samples t-test was used to compare variables between the two groups
Detailed description
Participants' selection:
22 patients, aged from 18 to 50 years, were selected in this prospective, randomized and blinded clinical trial from the Outpatient Clinic of the Department of Oral Medicine and Periodontology, Faculty of Dentistry, Kafrelsheikh University. Those subjects had inadequate bone volume for implant placement due to width insufficiency of maxillary anterior alveolar ridges. The research ethical committee of Faculty of Dentistry, Kafrelsheikh University approved the study (KD/06/21). Research procedures were explained to all patients, and they agreed to participate in the study and signed the appropriate informed consent form. The inclusion criteria implemented for patient selection were good general health at the time of surgery; at least 3months postextraction healing period; and horizontally compromised maxillary anterior alveolar ridges (at least 3mm bone width and 13mm bone height). The criteria of patients exclusion were vertical bone defect; thick labial cortex with less cancellous bone inside; obvious undercut on the labial/buccal side; uncontrolled periodontal conditions; history of radiotherapy in the head and neck region; uncontrolled diabetes mellitus or other systematic disorders; smokers; pregnancy; non-compliant patients; and allergic reaction to the used medications.
Pre-surgical therapy and grouping Pre-surgical therapy consisted of a thorough full-mouth scaling and root planning. Patients were randomly assigned immediately before surgery into two groups (11 patients each) by computer-assessed randomization software (Random Allocation Software, Version 1.0). Control group received ridge splitting with simultaneous implant placement in combination with autogenous bone graft alone, while study group used (1:1) mixture of autogenous and bioactive glass bone grafts. Bone volume was assessed two weeks before operation using CBCT (Scanora 3D, Soredex Oy, Tuusula, Finland).
Surgical procedure:
Operations were performed under local anesthesia. Mid-crestal incision followed by full thickness flap reflection to expose surgical site. Mid crestal cut using piezo-surgery unit (Piezotome® Cube, ACTEON®, Acteon Group Ltd, Norwich, England). Then, the cut was extended deep to the length of implant. Then, ridge was expanded progressively using bone wedges (Microdent Implant System, Spain). Implant location was marked, with a buccal bony wall as uniformly thick (>1 mm) as possible to avoid bone fracture. The implant site was prepared and 3.75*13 mm dental implant fixture (Humana Dental Implants \& Accessories GmbH, Germany) was placed stably in between the two bony plates.
Autogenous bone harvesting:
Incision was made at mucogingival junction in the symphysis area followed by full thickness flap reflection, and then corticocancellous bone was harvested using a trephine drill. Finally the flap was sutured by interrupted and horizontal mattress suture by 3-0 black silk.
In control group, harvested autogenous bone graft was used for augmentation of the gap between buccal and lingual plates. Study group received the same way of treatment except using (1:1) mixture of the harvested autogenous bone with bioactive glass bone graft (BonyGlass, Pharma-Excellence, Egypt). The wound was completely closed in a tension-free way. All surgeries were performed by the same operator.
Postoperative care:
Patients were prescribed amoxicillin-clavulanic acid 1g. every 12hours antibiotic (Augmentin 1g, SmithKline Beecham Pharmaceuticals), and 0.12% chlorhexidine hydrochloride mouth wash twice daily (Hexitol, ADCO, Cairo, A.R.E). The sutures were removed 14days postoperatively. No removable denture was allowed to wear for 2weeks.
6months postoperatively, clinical evaluation was recorded including implant survival, presence of infection, pain, tenderness or wound dehiscence. CBCT was taken at 6months postoperatively to evaluate ridge width and bone level. All clinical and radiographic measurements were recorded by one calibrated masked examiner.
Study variables The primary outcome variable was linear changes in the marginal bone surrounding the implants and alveolar ridge width, taken from cross-sectional and longitudinal CBCT images. Bone heights and width were assessed preoperatively and after 6months postoperatively using the CBCT images.
Statistical analysis:
Sample size calculation was undertaken via G power version 3.1 statistical software based on the following pre-established parameters: an alpha-type error of 0.05, a power test of 0.80, a total sample of 22 subjects (11 subjects for each group) appeared to be sufficient.
The statistical analysis was performed using IBM SPSS version 20 software (IBM Corp., Armonk, NY, USA). Data were presented as the mean+stanstandard deviation. The paired Student's t- test was used to compare the obtained results within the same group of patients at 2 different intervals. The independent samples t-test was used to compare variables between the two groups. In all tests, the result was considered statistically significant if the P-value was <0.05.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Factorial
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| autogenous bone graft | Active comparator | Procedure: autogenous bone graftautogenous bone graft for augmenting bone defects around dental implants placed simultaneously with ridge splitting |
| mix of bioactive glass and autogenous bone graft | Experimental | Procedure: mixture of bioactive glass and autogenous bone graft1:1 mix of bioactive glass and autogenous bone graft for augmenting bone defects around dental implants placed simultaneously with ridge splitting |
Who may qualify
- Ages
- 21 to 50 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (3 listed)
- good general health at the time of surgery
- at least 3months postextraction healing period
- horizontally compromised maxillary anterior alveolar ridges (at least 3mm bone width and 13mm bone vertical height).
Key exclusion criteria (10 listed)
- vertical bone defect
- thick labial cortex with less cancellous bone inside
- obvious undercut on the labial/buccal side
- uncontrolled periodontal conditions
- history of radiotherapy in the head and neck region
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| mixture of bioactive glass and autogenous bone graftbone expansion was performed and autogenous bone mixed with bioactive glass was used to augment the intercortical bone defect after ridge splitting and simultaneous dental implants | Procedure or surgery | mix of bioactive glass and autogenous bone graft |
| autogenous bone graftbone expansion was performed and autogenous bone alone was used to augment the intercortical bone defect after ridge splitting and simultaneous dental implants | Procedure or surgery | autogenous bone graft |
Primary outcome
Clinical measurements of pain intensity
Time frame: 6 months
pain intensity verbal rating scale either mild, moderate or sever
Clinical incidence of implants mobility
Time frame: 6 months
Implants mobility
measuring the survival rates
Time frame: 6 months
survival rates of implants
1 secondary outcome
radiographic results of bone width and height
Time frame: 6 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 May 2021.
- Derived from this study: PubMed 34367287Elamrousy W, Osama M, Issa DR. Autogenous Bone and Bioactive Glass around Implants Placed Simultaneously with Ridge Splitting for the Treatment of Horizontal Bony Defects: A Randomised Clinical Trial. Int J Dent. 2021 Jul 28;2021:2457328. doi: 10.1155/2021/2457328. eCollection 2021.
Related trials for Horizontal Alveolar Ridge Deficiency
Not yet recruiting
Autogenous and Xenograft Bone Mix in Alveolar Ridge Reconstruction
Horizontal Alveolar Ridge Deficiency
Not yet recruiting
Comparison of Three Autogenous Bone and Xenograft Ratios for Horizontal Ridge Augmentation
Horizontal Alveolar Ridge Deficiency
Not yet recruiting
Comparison of Two Autogenous Bone and Xenograft Ratios for Horizontal Ridge Augmentation
Horizontal Alveolar Ridge Deficiency
Not yet recruiting
Shell Technique for Implant Site Development
Ridge Augmentation, Ridge Deficiency
Recruiting
Histological and Histomorphometric Assessment With Inflammatory Profile Analysis of Bone Tissue After Horizontal Ridge Augmentation Using Customized Porous Zirconia Shell
Alveolar Bone Loss, Alveolar Ridge Deficiency
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing mixture of bioactive glass and autogenous bone graft and autogenous bone graft in people with Horizontal Alveolar Ridge Deficiency, run by Kafrelsheikh University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 4 May 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Clinical measurements of pain intensity (time frame: 6 months). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04814160, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 May 2021.